GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HPGC Renmintongtai Pharmaceutical Corp (SHSE:600829) » Definitions » Debt-to-Asset

HPGC Renmintongtai Pharmaceutical (SHSE:600829) Debt-to-Asset : 0.16 (As of Mar. 2024)


View and export this data going back to 1994. Start your Free Trial

What is HPGC Renmintongtai Pharmaceutical Debt-to-Asset?

HPGC Renmintongtai Pharmaceutical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥1,139 Mil. HPGC Renmintongtai Pharmaceutical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥17 Mil. HPGC Renmintongtai Pharmaceutical's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was ¥7,353 Mil. HPGC Renmintongtai Pharmaceutical's debt to asset for the quarter that ended in Mar. 2024 was 0.16.


HPGC Renmintongtai Pharmaceutical Debt-to-Asset Historical Data

The historical data trend for HPGC Renmintongtai Pharmaceutical's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HPGC Renmintongtai Pharmaceutical Debt-to-Asset Chart

HPGC Renmintongtai Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.11 0.20 0.18 0.14

HPGC Renmintongtai Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.15 0.16 0.14 0.16

Competitive Comparison of HPGC Renmintongtai Pharmaceutical's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, HPGC Renmintongtai Pharmaceutical's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HPGC Renmintongtai Pharmaceutical's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HPGC Renmintongtai Pharmaceutical's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where HPGC Renmintongtai Pharmaceutical's Debt-to-Asset falls into.



HPGC Renmintongtai Pharmaceutical Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

HPGC Renmintongtai Pharmaceutical's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(989.773 + 29.409) / 7426.465
=0.14

HPGC Renmintongtai Pharmaceutical's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1138.617 + 17.147) / 7353.03
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HPGC Renmintongtai Pharmaceutical  (SHSE:600829) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


HPGC Renmintongtai Pharmaceutical Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of HPGC Renmintongtai Pharmaceutical's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


HPGC Renmintongtai Pharmaceutical (SHSE:600829) Business Description

Traded in Other Exchanges
N/A
Address
No. 76 Hengshan Road, Nangang District, Heilongjiang Province, Harbin, CHN, 150076
HPGC Renmintongtai Pharmaceutical Corp, formerly Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co Ltd is engaged in the production and sale of pharmaceuticals products in China.
Executives
Yue Xian Zhi senior management
Zhang Li Jun Director

HPGC Renmintongtai Pharmaceutical (SHSE:600829) Headlines

No Headlines